Table 1 Patient characteristics

From: A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma

Total number of patients

30

Sex

 

 Male

16

 Female

14

Age (years)

 

 Median

54

 Range

40–81

ECOG performance status

 

 0

16

 1

10

 2

4

Time to distant progression from diagnosis (months)

 Median

35.4

 Range

0–126

Site of disease

 

 Skin/soft tissue

14

 Nodal disease

9

 Lung

15

 Liver

11

 Brain

11

 Bone

5

 Visceral disease (nonhepatic)

4

 Single site only

8

ECOG=Eastern Cooperative Oncology Group.